Effects of Traditional Chinese Medicine Adjuvant Therapy on the Survival of Patients with Primary Liver Cancer

Aim. This study aims to evaluate whether adjuvant traditional Chinese medicine (TCM) can improve the survival of patients with primary liver cancer (PLC). Methods. A total of 1,859 patients with PLC at Beijing Ditan Hospital between August 2008 and September 2017 were included. The patients were div...

Full description

Saved in:
Bibliographic Details
Published in:Evidence-based complementary and alternative medicine 2022, Vol.2022, p.9810036-10
Main Authors: Hou, Jie, Shi, Ke, Liu, Yao, Chen, Jialiang, Ran, Chongping, Wang, Xianbo
Format: Article
Language:English
Subjects:
Ablation
Adjuvant therapy
Adjuvants
Cancer therapies
Chemotherapy
Chinese medicine
FDA approval
Hepatitis
Hospitals
Liver cancer
Medical prognosis
Mortality
Patients
Survival
Survival analysis
Traditional Chinese medicine
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim. This study aims to evaluate whether adjuvant traditional Chinese medicine (TCM) can improve the survival of patients with primary liver cancer (PLC). Methods. A total of 1,859 patients with PLC at Beijing Ditan Hospital between August 2008 and September 2017 were included. The patients were divided into TCM and control groups according to whether the patients took TCM for ≥3 months. There were 1,111 patients in the TCM group and 748 in the control group. Univariate and multivariate Cox regression analyses were used to analyze the factors affecting the 3-year survival of patients with PLC. To reduce selection bias, 1 : 1 propensity score matching (PSM) was performed between the two groups. The overall survival outcomes were evaluated using the Kaplan–Meier (K–M) survival curve, and the log-rank test was used to compare the differences in survival curves. Results. After multivariate Cox regression analysis, TCM was an independent favorable factor for the 3-year survival of patients with PLC (adjusted hazard ratio (aHR) 0.359, 95% confidence interval (CI) 0.292–0.441, P
ISSN:1741-427X
1741-4288
DOI:10.1155/2022/9810036